LumiThera, Inc.

Silver Sponsor

LumiThera, Inc. is harnessing the power of light to develop and commercialize light-based innovations that accurately diagnose, monitor, and treat blinding diseases of the eye (degenerative eye disease).

LumiThera’s flagship product, the Valeda® Light Delivery System, uses multiwavelength photobiomodulation (PBM) to treat dry age-related macular degeneration (AMD). Doctors utilizing Valeda in their clinics have delivered over 500,000 treatments to dry AMD patients in the UK, Europe, and Latin America. Valeda is CE Marked in the EU and is available in select countries in Latin America. Valeda is not cleared by the Food & Drug Administration (FDA).

AdaptDx Pro® dark adaptation functional testing technology enables doctors to detect and monitor AMD three years before clinical presentation. AdaptDx Pro is listed on the FDA’s Establishment Registration & Device Listing.

Diopsys® ERG and VEP systems help doctors analyze the entire pathway for visual and neuro- visual disorders. VEP is FDA-cleared. ERG and VEP are available in select countries outside of the USA.

For more information on the Valeda® Light Delivery System, visit www.lumithera.com.

The AdaptDx Pro and Diopsys ERG and VEP systems are available separately through LumiThera Diagnostics, Inc. and Diopsys, Inc.

Watch our promo video

SPEAKING SCHEDULE AT PBM2024

CONNECT WITH OUR TEAM AT PBM2024